294 related articles for article (PubMed ID: 28640111)
1. Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
Chin HJ; Nam JH; Lee EK; Shin JY
Medicine (Baltimore); 2017 Jun; 96(25):e7213. PubMed ID: 28640111
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.
Park SH; Jeong HE; Oh IS; Hong SM; Yu SH; Lee CB; Shin JY
Diabetes Obes Metab; 2021 Jun; 23(6):1232-1241. PubMed ID: 33502058
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
[TBL] [Abstract][Full Text] [Related]
5. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
6. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
[TBL] [Abstract][Full Text] [Related]
8. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Komamine M; Kajiyama K; Ishiguro C; Uyama Y
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
[TBL] [Abstract][Full Text] [Related]
10. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
Baksh S; Wen J; Mansour O; Chang HY; McAdams-DeMarco M; Segal JB; Ehrhardt S; Alexander GC
Sci Rep; 2021 Aug; 11(1):16637. PubMed ID: 34404825
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
14. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
15. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Yu OH; Yin H; Azoulay L
Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
[TBL] [Abstract][Full Text] [Related]
18. The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
Hong JL; Buse JB; Jonsson Funk M; Pate V; Stürmer T
Diabetes Care; 2018 Jun; 41(6):1196-1203. PubMed ID: 29618573
[TBL] [Abstract][Full Text] [Related]
19. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
